ClinicalTrials.gg
CompletedNCT01578499ALCANZAUpdated Jan 5, 2021Results posted

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)

A Phase 3 interventional study of Brentuximab Vedotin and Methotrexate in Primary Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides and Cutaneous T-Cell Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 41 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-05.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 360 studies in Mycosis Fungoides with a site in United States — 24 open to participants now, 36 under way, none of them phase 3. Mycosis Fungoides · United States.

Enrollment
23rd of 279
131 · median 32
Started
2012
with 8 others
Phase 3
19 of 360
none open now
Registered
266th of 360
by date

Among the 360 studies in Mycosis Fungoides with a site in United States, this one is the 23rd largest by enrollment of the 279 interventional ones that give a count, is one of 9 that started in 2012, is one of 19 in phase 3, and was the 266th registered.

Mycosis Fungoides

447 studies on the registry are indexed under Mycosis Fungoides; 42 are open to participants now.

Browse Mycosis Fungoides studies →

Open to participants now

24 of the 360 studies in Mycosis Fungoides with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Mycosis Fungoides studies recruiting now, 25 (83%) set no upper age limit and 1 (3%) stops at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 360 studies in Mycosis Fungoides with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine objective response rate (ORR), lasting at least 4 months (ORR4), with brentuximab vedotin in participants with cluster of differentiation antigen 30 positive (CD30+) cutaneous T-cell lymphoma [mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL) ]compared to that achieved with therapy in the control arm.

Read the detailed description

The drug being tested in this study is called brentuximab vedotin. Brentuximab vedotin is being tested to treat people who have CD30+ cutaneous T-cell lymphoma (mycosis fungoides and primary cutaneous anaplastic large cell lymphoma). This study will look at the overall response of people who took brentuximab vedotin compared to people who took methotrexate or bexarotene as standard care.

The study enrolled 131 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  • Methotrexate 5 to 50 mg or Bexarotene 300 mg/m\^2 (as per physician's choice)
  • Brentuximab vedotin 1.8 mg/kg

This multicenter trial is being conducted worldwide. The overall time to participate in this study is approximately 6 years. Participants will make multiple visits to the clinic every 12 weeks for a minimum of 24 months after the end of treatment (EOT) visit, and then every 6 months until death, study closure, or 6 years after enrollment of the last participant.

03

Conditions studied

  • Primary Cutaneous Anaplastic Large Cell Lymphoma
  • Mycosis Fungoides
  • Cutaneous T-Cell Lymphoma

Keywords

  • Brentuximab vedotin
  • ALCANZA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary consent form
  • Male or female participants 18 years or older with diagnosis of mycosis fungoides (MF) or primary cutaneous anaplastic large cell lymphoma (pcALCL)
  • Participants with pcALCL who have received prior radiation therapy or at least 1 prior systemic therapy; participants with MF who have received at least 1 prior systemic therapy
  • confirmed CD30+ disease by central laboratory assessment and pathology review
  • (ECOG) performance status ≤ 2
  • Female participants who are post menopausal, surgically sterile, or agree to practice 2 effective methods of or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant
  • Male participants who agree to practice effective barrier contraception or agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the participant
  • Clinical laboratory values as specified in protocol
  • A 3-week is required from previous treatments (with the exception of a 12-week washout for antibody-directed or immunoglobulin-based immune therapy, or other monoclonal antibody therapies), unless it is not in the best interest of the patient in the opinion of the investigator. Individual cases should be discussed with the project clinician before enrollment.

Exclusion criteria

Exclusion Criteria:

  • A concurrent diagnosis of systemic ALCL, or other non Hodgkin lymphoma (excluding LyP) or Sezary syndrome or B2 disease
  • Participants with cardiovascular conditions specified in protocols
  • Participants with history of another primary not in remission for at least 3 years
  • Known active cerebral/meningeal disease, including signs or symptoms of progressive multifocal leukoencephalopathy (PML);
  • Known (HIV) infection, or infection
  • Oral retinoid therapy for any indication within 3 weeks of study entry
  • therapy within 3 weeks or chemotherapy or any antibody-directed or immunoglobulin-based immune therapy (e.g., immunoglobulin replacement, other monoclonal antibody therapies) within 12 weeks of first dose of study drug
  • Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 of any cycle
  • Previous receipt of brentuximab vedotin Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.

Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    Brentuximab vedotin

    Brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).

    Drug: Brentuximab Vedotin

  • Active comparator
    Methotrexate or Bexarotene

    Methotrexate 5 to 50 mg, tablets, orally, once weekly (dose adjustment is guided by patient response and toxicity) or Bexarotene 300 mg/m\^2, tablets, orally, once daily with meals for up to 48 weeks.

    Drug: Methotrexate · Drug: Bexarotene

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4)

    ORR4 was determined by an Independent Review Facility (IRF) based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral radiographic assessment by an IRF and for the participants with mycosis fungoides (MF) only, detection of circulation Sezary cells. Participants whose first response occurred after the start of subsequent anticancer therapy were excluded. Response Criteria was based on International Society for Cutaneous Lymphomas (ISCL), United States Cutaneous Lymphoma Consortium (USCLC) and Cutaneous Lymphoma Task Force (CLTF) of the European Organisation for Research and Treatment of Cancer (EORTC) Consensus guidelines (Olsen, 2011).

    Time frame: Each Cycle until disease progression, death End of treatment (Median overall follow-up 38.8 months)

Secondary outcomes

  1. Percentage of Participants Achieving a CR

    Complete Response (CR) was determined by the IRF based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral radiographic and for the participants with mycosis fungoides (MF) only, detection of circulation Sezary cells. Response Criteria was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).

    Time frame: Each Cycle until disease progression, death or data cutoff (Median overall follow-up 38.8 months)

  2. Progression-Free Survival (PFS)

    PFS was assessed by the IRF and is defined as the time from randomization until disease progression or death due to any cause, whichever occurs first. Disease progression was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).

    Time frame: Until disease progression, death or data cutoff (Median PFS follow-up of 38.8 months)

  3. Maximum Change From Baseline in Symptom Domain Score of the Skindex-29 Questionnaire

    Skindex-29 is a 29-item dermatology-specific health-related quality of life (HRQoL). The Skindex-29 incorporates a 28-day recall period and consists of 3 domains: symptoms, emotions, and functioning. The domain scores and an overall score are expressed on a 100-point scale, from 0 to 100 with higher scores indicating lower levels of health- HRQoL. A negative change (reduction) from Baseline indicates improvement.

    Time frame: Baseline up to End of Treatment (Week 52)

  4. Duration of Response (DOR)

    Duration of response was assessed by the IRF in participants with confirmed response \[CR or Partial Response (PR)\] and is defined as the time between first documentation of response and disease progression. Response Criteria was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).

    Time frame: Until disease progression, death or data cutoff (Median follow-up 38.8 months)

  5. DOR of Skin Response

    Duration of skin response (CR and PR) was assessed by the investigator and is defined as the time between the first skin response to progressive disease in skin. Per mSWAT, CR is defined as 100% clearance of skin lesions. PR is defined as 50%-99% clearance of skin disease from Baseline; No new tumors in participants without tumors at Baseline -MF; No new tumors-primary cutaneous anaplastic large cell lymphoma (pcALCL).Progressive disease is defined as ≥ 25% increase in skin disease from baseline, or loss of response: in those with CR or PR, increase of skin score of greater than the sum of nadir plus 50% baseline score, or new tumors in participants without tumors at baseline (MF).

    Time frame: Until disease progression, death or data cutoff (Median follow-up 38.8 months)

  6. Event-Free Survival (EFS)

    EFS was assessed by the IRF and is defined as the time from randomization until any cause of treatment failure: disease progression, discontinuation of treatment for any reason, or death due to any cause, whichever occurs first. Disease progression was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).

    Time frame: From randomization until disease progression, death or data cutoff (Median follow-up 36.8 months)

  7. Cmax: Maximum Observed Concentration for Brentuximab Vedotin

    Time frame: Day 1 pre-dose and 30 minutes after infusion in Cycles 1 and 3

  8. Ctrough: Observed Concentration at the End of a Dosing Interval for Brentuximab Vedotin

    Time frame: Day 1 pre-dose of Cycles 2 and 4

  9. Cmax: Maximum Observed Concentration for Monomethyl Auristatin (MMAE) for Brentuximab Vedotin

    Time frame: Day 1 pre-dose and 30 minutes after infusion ended in Cycles 1 and 3

  10. Ctrough: Observed Concentration at the End of a Dosing Interval for MMAE for Brentuximab Vedotin

    Time frame: Day 1 pre-dose of Cycles 2 and 4

  11. Number of Participants With Antitherapeutic Antibodies (ATA) to Brentuximab Vedotin

    Blood was collected and evaluated for ATA and neutralizing ATA in all participants who received brentuximab vedotin to assess immunogenicity.

    Time frame: Baseline up to End of Treatment (Week 52)

  12. Change From Baseline in the Skindex-29 Questionnaire Total Score

    Skindex-29 is a 29-item dermatology-specific health-related quality of life (HRQoL). The Skindex-29 incorporates a 28-day recall period and consists of 3 domains: symptoms, emotions, and functioning. The domain scores and an overall score are expressed on a 100-point scale, 0 to 100 with higher scores indicating lower levels of health- HRQoL. A negative change (reduction) from Baseline indicates improvement.

    Time frame: Day 1 of Cycles 1, 2, 4, 6, 8, 10, 12, 14, 16, at End of Treatment (EOT) and during posttreatment long treatment follow-up (LTFU) - (Median follow-up 38.8 months)

  13. Change From Baseline in Functional Assessment of Cancer Therapy General Questionnaire (FACT-G) Score

    FACT-G is a 27-item general cancer QOL instrument completed by participants receiving cancer treatment. FACT-G incorporates a 7-day recall period and contains 4 primary subscales: Physical Well-Being (PWB; sum of 7 items, point range 0-28); Social/Family Well-Being (SWB, sum of 7-items, point range 0-28); Emotional Well-Being (EWB; sum of 6-items, point range 0-24); Functional Well-Being (FWB; sum of 7-items, point range 0-28); Fact-G total score=sum of PWB, SWB, EWB, FWB, point range 0-108. Higher scores for the total scales and subscales indicate better quality of life. A negative change (reduction) from Baseline indicates improvement.

    Time frame: Day 1 of Cycles 1, 2, 4, 6, 8, 10, 12, 14, 16, at EOT and during posttreatment (LTFU) - (Median follow-up 38.8 months)

  14. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AEs and SAEs were assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event.

    Time frame: First dose of study drug through 30 days after last dose of study drug (Up to 450 days)

07

Results

Posted Mar 16, 2018

Participant flow

Participants took part in the study at 34 investigative sites in Australia, Belgium, Brazil, France, Germany, Italy, Poland, Spain, Switzerland, United Kingdom, United States from 11 June 2012 to the Primary Completion data of 06 July 2018.

Participant flow — Overall Study
MilestoneBrentuximab VedotinMethotrexate or Bexarotene
Started6665
Safety population: treated6662
Intent to treat population: cd30+6464
Completed3222
Not completed3443
Withdrew: Reason not specified01
Withdrew: Lost to follow-up21
Withdrew: Withdrawal by subject1016
Withdrew: Death2025
Withdrew: Died and end of study page not completed20

Outcome measures

PrimaryPercentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4)

ORR4 was determined by an Independent Review Facility (IRF) based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral radiographic assessment by an IRF and for the participants with mycosis fungoides (MF) only, detection of circulation Sezary cells. Participants whose first response occurred after the start of subsequent anticancer therapy were excluded. Response Criteria was based on International Society for Cutaneous Lymphomas (ISCL), United States Cutaneous Lymphoma Consortium (USCLC) and Cutaneous Lymphoma Task Force (CLTF) of the European Organisation for Research and Treatment of Cancer (EORTC) Consensus guidelines (Olsen, 2011).

Time frame:
Each Cycle until disease progression, death End of treatment (Median overall follow-up 38.8 months)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4)
percentage of participantsBrentuximab VedotinMethotrexate or Bexarotene
Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4)54.7 (42.5 to 66.9)12.5 (4.4 to 20.6)
Statistical analysis
  • Brentuximab Vedotin vs Methotrexate or Bexarotene · Cochran-Mantel-Haenszel · p = <0.001 (P-value was stratified by baseline disease diagnosis (pcALCL and MF).) · Risk difference (rd): 42.2 · 95% CI 27.5 to 56.8
SecondaryPercentage of Participants Achieving a CR

Complete Response (CR) was determined by the IRF based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral radiographic and for the participants with mycosis fungoides (MF) only, detection of circulation Sezary cells. Response Criteria was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).

Time frame:
Each Cycle until disease progression, death or data cutoff (Median overall follow-up 38.8 months)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a CR
percentage of participantsBrentuximab VedotinMethotrexate or Bexarotene
Percentage of Participants Achieving a CR17.2 (7.9 to 26.4)1.6 (0.0 to 8.4)
Statistical analysis
  • Brentuximab Vedotin vs Methotrexate or Bexarotene · Cochran-Mantel-Haenszel · p = 0.0002 (P-value was stratified by baseline disease diagnosis (pcALCL and MF).) · Risk difference (rd): 15.6 · 95% CI -2.5 to 33.0
SecondaryProgression-Free Survival (PFS)

PFS was assessed by the IRF and is defined as the time from randomization until disease progression or death due to any cause, whichever occurs first. Disease progression was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).

Time frame:
Until disease progression, death or data cutoff (Median PFS follow-up of 38.8 months)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsBrentuximab VedotinMethotrexate or Bexarotene
Progression-Free Survival (PFS)16.7 (15.4 to 21.6)3.5 (2.4 to 4.6)
Statistical analysis
  • Brentuximab Vedotin vs Methotrexate or Bexarotene · Log Rank · p = <0.001 · Hazard ratio (hr): 0.378 · 95% CI 0.247 to 0.577
SecondaryMaximum Change From Baseline in Symptom Domain Score of the Skindex-29 Questionnaire

Skindex-29 is a 29-item dermatology-specific health-related quality of life (HRQoL). The Skindex-29 incorporates a 28-day recall period and consists of 3 domains: symptoms, emotions, and functioning. The domain scores and an overall score are expressed on a 100-point scale, from 0 to 100 with higher scores indicating lower levels of health- HRQoL. A negative change (reduction) from Baseline indicates improvement.

Time frame:
Baseline up to End of Treatment (Week 52)
Reported as:
Mean · score on a scale
Maximum Change From Baseline in Symptom Domain Score of the Skindex-29 Questionnaire
score on a scaleBrentuximab VedotinMethotrexate or Bexarotene
Maximum Change From Baseline in Symptom Domain Score of the Skindex-29 Questionnaire-28.08 ± 26.863-8.62 ± 17.013
Statistical analysis
  • Brentuximab Vedotin vs Methotrexate or Bexarotene · ANCOVA · p = <0.001 · Estimate of difference: -19.0 · 95% CI -26.7 to -11.4
SecondaryDuration of Response (DOR)

Duration of response was assessed by the IRF in participants with confirmed response \[CR or Partial Response (PR)\] and is defined as the time between first documentation of response and disease progression. Response Criteria was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).

Time frame:
Until disease progression, death or data cutoff (Median follow-up 38.8 months)
Reported as:
Median · months
Duration of Response (DOR)
monthsBrentuximab VedotinMethotrexate or Bexarotene
Duration of Response (DOR)15.1 (9.8 to 25.5)18.4 (3.5 to NA)
SecondaryDOR of Skin Response

Duration of skin response (CR and PR) was assessed by the investigator and is defined as the time between the first skin response to progressive disease in skin. Per mSWAT, CR is defined as 100% clearance of skin lesions. PR is defined as 50%-99% clearance of skin disease from Baseline; No new tumors in participants without tumors at Baseline -MF; No new tumors-primary cutaneous anaplastic large cell lymphoma (pcALCL).Progressive disease is defined as ≥ 25% increase in skin disease from baseline, or loss of response: in those with CR or PR, increase of skin score of greater than the sum of nadir plus 50% baseline score, or new tumors in participants without tumors at baseline (MF).

Time frame:
Until disease progression, death or data cutoff (Median follow-up 38.8 months)
Reported as:
Median · months
DOR of Skin Response
monthsBrentuximab VedotinMethotrexate or Bexarotene
DOR of Skin Response18.9 (15.0 to 25.7)18.3 (3.5 to NA)
SecondaryEvent-Free Survival (EFS)

EFS was assessed by the IRF and is defined as the time from randomization until any cause of treatment failure: disease progression, discontinuation of treatment for any reason, or death due to any cause, whichever occurs first. Disease progression was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).

Time frame:
From randomization until disease progression, death or data cutoff (Median follow-up 36.8 months)
Reported as:
Median · months
Event-Free Survival (EFS)
monthsBrentuximab VedotinMethotrexate or Bexarotene
Event-Free Survival (EFS)9.4 (5.9 to 11.7)2.3 (1.7 to 3.5)
SecondaryCmax: Maximum Observed Concentration for Brentuximab Vedotin
Time frame:
Day 1 pre-dose and 30 minutes after infusion in Cycles 1 and 3
Reported as:
Mean · ug/mL
Cmax: Maximum Observed Concentration for Brentuximab Vedotin
ug/mLpcALCL: Brentuximab VedotinMF: Brentuximab Vedotin 1.8 mg/kg
Cycle 1 Day 138.36 ± 9.42738.40 ± 8.912
Cycle 3 Day 140.14 ± 12.69736.69 ± 14.249
SecondaryCtrough: Observed Concentration at the End of a Dosing Interval for Brentuximab Vedotin
Time frame:
Day 1 pre-dose of Cycles 2 and 4
Reported as:
Mean · ug/mL
Ctrough: Observed Concentration at the End of a Dosing Interval for Brentuximab Vedotin
ug/mLpcALCL: Brentuximab VedotinMF: Brentuximab Vedotin 1.8 mg/kg
Cycle 2 Day 13.57 ± 10.1010.58 ± 0.517
Cycle 4 Day 10.99 ± 0.5280.78 ± 0.446
SecondaryCmax: Maximum Observed Concentration for Monomethyl Auristatin (MMAE) for Brentuximab Vedotin
Time frame:
Day 1 pre-dose and 30 minutes after infusion ended in Cycles 1 and 3
Reported as:
Mean · ng/mL
Cmax: Maximum Observed Concentration for Monomethyl Auristatin (MMAE) for Brentuximab Vedotin
ng/mLpcALCL: Brentuximab VedotinMF: Brentuximab Vedotin 1.8 mg/kg
Cycle 1 Day 12.53 ± 1.3823.34 ± 1.901
Cycle 3 Day 12.96 ± 1.1763.08 ± 1.276
SecondaryCtrough: Observed Concentration at the End of a Dosing Interval for MMAE for Brentuximab Vedotin
Time frame:
Day 1 pre-dose of Cycles 2 and 4
Reported as:
Mean · ng/mL
Ctrough: Observed Concentration at the End of a Dosing Interval for MMAE for Brentuximab Vedotin
ng/mLpcALCL: Brentuximab VedotinMF: Brentuximab Vedotin 1.8 mg/kg
Cycle 2 Day 10.11 ± 0.0950.09 ± 0.060
Cycle 4 Day 10.14 ± 0.1130.11 ± 0.091
SecondaryNumber of Participants With Antitherapeutic Antibodies (ATA) to Brentuximab Vedotin

Blood was collected and evaluated for ATA and neutralizing ATA in all participants who received brentuximab vedotin to assess immunogenicity.

Time frame:
Baseline up to End of Treatment (Week 52)
Reported as:
Number · participants
Number of Participants With Antitherapeutic Antibodies (ATA) to Brentuximab Vedotin
participantspcALCL: Brentuximab VedotinMF: Brentuximab Vedotin 1.8 mg/kg
Immunogenicity-evaluable participants1446
Baseline Negative: ATA negative823
Baseline Negative: ATA positive619
Baseline Negative: Transiently Positive49
Baseline Negative: Persistently Positive210
Baseline Negative: Neutralizing ATA Positive414
Baseline Positive: ATA Negative01
Baseline Positive: ATA Positive03
Baseline Positive: Transiently Positive03
Baseline Positive: Persistently Positive00
Baseline Positive: Neutralizing ATA Positive02
SecondaryChange From Baseline in the Skindex-29 Questionnaire Total Score

Skindex-29 is a 29-item dermatology-specific health-related quality of life (HRQoL). The Skindex-29 incorporates a 28-day recall period and consists of 3 domains: symptoms, emotions, and functioning. The domain scores and an overall score are expressed on a 100-point scale, 0 to 100 with higher scores indicating lower levels of health- HRQoL. A negative change (reduction) from Baseline indicates improvement.

Time frame:
Day 1 of Cycles 1, 2, 4, 6, 8, 10, 12, 14, 16, at End of Treatment (EOT) and during posttreatment long treatment follow-up (LTFU) - (Median follow-up 38.8 months)
Reported as:
Mean · score on a scale
Change From Baseline in the Skindex-29 Questionnaire Total Score
score on a scaleBrentuximab VedotinMethotrexate or Bexarotene
Change at Cycle 2-5.44 ± 11.055-2.49 ± 11.959
Change at Cycle 4-14.60 ± 17.488-6.71 ± 9.755
Change at Cycle 6-17.59 ± 17.770-5.40 ± 9.758
Change at Cycle 8-21.73 ± 18.882-7.28 ± 16.769
Change at Cycle 10-22.47 ± 21.722-3.71 ± 21.752
Change at Cycle 12-23.37 ± 21.555-5.22 ± 17.704
Change at Cycle 14-19.72 ± 20.980-7.49 ± 22.463
Change at Cycle 16-19.35 ± 18.9110.75 ± 10.308
Change at End of Treatment-16.26 ± 23.281-0.96 ± 18.973
Change at 3-6 months LTFU-1.07 ± 3.704-9.48 ± 21.629
Change at 6-9 months LTFU-8.04 ± 8.800-9.68 ± 17.789
Change at 9-12 months LTFU-7.94 ± 15.582-4.93 ± 14.516
Change at 12-15 months LTFU-16.21 ± 18.438-11.16 ± 18.183
Change at 15-18 months LTFU-19.18 ± 19.475-8.53 ± 12.768
Change at 18-21 months LTFU-19.27 ± 20.962-5.46 ± 16.679
Change at 21-24 months LTFU-16.60 ± 19.875-6.86 ± 14.991
Change at 24-27 months LTFU-17.04 ± 15.982-9.05 ± 23.990
Change at 27-30 months LTFU-12.45 ± 19.639-7.97 ± 16.401
Change at >30 months LTFU-11.49 ± 22.470-1.07 ± 18.886
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy General Questionnaire (FACT-G) Score

FACT-G is a 27-item general cancer QOL instrument completed by participants receiving cancer treatment. FACT-G incorporates a 7-day recall period and contains 4 primary subscales: Physical Well-Being (PWB; sum of 7 items, point range 0-28); Social/Family Well-Being (SWB, sum of 7-items, point range 0-28); Emotional Well-Being (EWB; sum of 6-items, point range 0-24); Functional Well-Being (FWB; sum of 7-items, point range 0-28); Fact-G total score=sum of PWB, SWB, EWB, FWB, point range 0-108. Higher scores for the total scales and subscales indicate better quality of life. A negative change (reduction) from Baseline indicates improvement.

Time frame:
Day 1 of Cycles 1, 2, 4, 6, 8, 10, 12, 14, 16, at EOT and during posttreatment (LTFU) - (Median follow-up 38.8 months)
Reported as:
Mean · score on a scale
Change From Baseline in Functional Assessment of Cancer Therapy General Questionnaire (FACT-G) Score
score on a scaleBrentuximab VedotinMethotrexate or Bexarotene
Change at Cycle 21.43 ± 10.168-0.37 ± 11.723
Change at Cycle 41.75 ± 12.0141.78 ± 10.740
Change at Cycle 64.23 ± 14.2572.24 ± 13.108
Change at Cycle 85.96 ± 16.0302.54 ± 10.809
Change at Cycle 106.61 ± 16.9714.38 ± 15.040
Change at Cycle 127.94 ± 18.8378.61 ± 21.024
Change at Cycle 149.04 ± 14.10410.75 ± 13.615
Change at Cycle 165.08 ± 9.2307.88 ± 23.432
Change at End of Treatment0.35 ± 16.067-2.29 ± 17.171
Change at 3-6 months LTFU16.00 ± 18.385-2.92 ± 8.367
Change at 6-9 months LTFU-0.19 ± 19.648-2.59 ± 12.473
Change at 9-12 months LTFU3.62 ± 17.651-5.32 ± 10.555
Change at 12-15 months LTFU8.33 ± 14.918-1.34 ± 11.905
Change at 15-18 months LTFU3.03 ± 12.6182.94 ± 14.756
Change at 18-21 months LTFU3.35 ± 11.117-0.19 ± 14.316
Change at 21-24 months LTFU1.51 ± 5.4710.61 ± 14.505
Change at 24-27 months LTFU4.20 ± 7.9521.42 ± 17.870
Change at 27-30 months LTFU-1.57 ± 17.4881.93 ± 8.716
Change at >30 months LTFU-6.22 ± 15.222-2.85 ± 5.518
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

AEs and SAEs were assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event.

Time frame:
First dose of study drug through 30 days after last dose of study drug (Up to 450 days)
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsBrentuximab VedotinMethotrexate or Bexarotene
AEs6356
SAEs1818

Adverse events

Collected over All-Cause mortality: Baseline up to End of study (Up to 6 years); Serious and Other adverse events: First dose of study drug through 30 days after last dose of study drug (Up to 450 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brentuximab Vedotin22/66 (33.3%)18/66 (27.3%)60/66 (90.9%)
Methotrexate or Bexarotene25/62 (40.3%)18/62 (29%)51/62 (82.3%)
Most frequent serious events
Showing 10 of 45
Most frequent serious events
EventBrentuximab VedotinMethotrexate or Bexarotene
PyrexiaGeneral disorders2/664/62
SepsisInfections and infestations1/663/62
CellulitisInfections and infestations2/660/62
Superinfection bacterialInfections and infestations0/661/62
UrosepsisInfections and infestations0/661/62
ParotitisInfections and infestations0/661/62
Periorbital infectionInfections and infestations0/661/62
ErysipelasInfections and infestations0/661/62
NeuralgiaNervous system disorders0/661/62
HypernatraemiaMetabolism and nutrition disorders0/661/62
Most frequent other events
Showing 10 of 50
Most frequent other events
EventBrentuximab VedotinMethotrexate or Bexarotene
Peripheral sensory neuropathyNervous system disorders31/661/62
NauseaGastrointestinal disorders24/669/62
FatigueGeneral disorders18/6618/62
DiarrhoeaGastrointestinal disorders18/664/62
HypertriglyceridaemiaMetabolism and nutrition disorders1/6611/62
VomitingGastrointestinal disorders11/663/62
PruritusSkin and subcutaneous tissue disorders11/668/62
AlopeciaSkin and subcutaneous tissue disorders10/662/62
Decreased appetiteMetabolism and nutrition disorders10/663/62
PyrexiaGeneral disorders9/668/62

Baseline characteristics

Safety population included participants who received at least 1 dose of study drug, analyzed according to the actual treatment received (n=66,62). Intent-to-treat population (ITT) population included all participants who were identified as CD30+ by the Ventana anti-CD30 (Ber-H2) assay and were randomized to treatment (n=64,64).

Age, Continuous
Age, Continuous(years)Brentuximab VedotinMethotrexate or BexaroteneTotal
Mean59.4 ± 13.8056.6 ± 14.4358.0 ± 14.12
Sex: Female, Male
Sex: Female, Male(Participants)Brentuximab VedotinMethotrexate or BexaroteneTotal
Female332861
Male333467
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Brentuximab VedotinMethotrexate or BexaroteneTotal
White5653109
Black or African American336
Asian156
Not reported314
Other123
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Brentuximab VedotinMethotrexate or BexaroteneTotal
Hispanic or Latino268
Not Hispanic or Latino6050110
Not reported2810
Region of Enrollment
Region of Enrollment(Participants)Brentuximab VedotinMethotrexate or BexaroteneTotal
Australia12820
Belgium426
France437
Germany325
Italy12618
Poland213
Spain235
Switzerland336
United Kingdom81523
United States141731
Brazil224
08

Study locations

41 sites
  • Los Angeles, California, United States
  • Palo Alto, California, United States
  • Chicago, Illinois, United States
  • Boston, Massachusetts, United States
  • Hackensack, New Jersey, United States
  • New York, New York, United States
  • Pittsburgh, Pennsylvania, United States
  • Houston, Texas, United States
  • Concord, New South Wales, Australia
  • South Brisbane, Queensland, Australia
  • Adelaide, South Australia, Australia
  • Nedlands, Western Australia, Australia
  • East Melbourne, Australia
  • St. Poelten, Austria
  • Wien, Austria
  • Leuven, Belgium
  • Sao Paulo, Brazil
  • Nantes Cedex 01, France
  • Paris, France
  • Pessac Cedex, France
  • Pierre Benite, France
  • Reims, France
  • Kiel, Germany
  • Krefeld, Germany
  • Mainz, Germany
  • Mannheim, Germany
  • Minden, Germany
  • Wurzburg, Germany
  • Bologna, Italy
  • Firenze, Italy
  • Meldola, Italy
  • Warszawa, Poland
  • Pamplona, Navarra, Spain
  • Barcelona, Spain
  • Madrid, Spain
  • Zurich, Switzerland
  • Leeds, West Yorkshire, United Kingdom
  • Birmingham, United Kingdom
  • Glasgow, United Kingdom
  • London, United Kingdom
  • Manchester, United Kingdom
09

References and documents

Publications

  • Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021 Dec 14;5(23):5098-5106. doi: 10.1182/bloodadvances.2021004710. Erratum In: Blood Adv. 2024 May 14;8(9):2243. doi: 10.1182/bloodadvances.2024012976. PubMed 34507350 ↗
  • Kim YH, Prince HM, Whittaker S, Horwitz SM, Duvic M, Bechter O, Sanches JA, Stadler R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown LC, Ortiz-Romero PL, Akilov OE, Trotman J, Taylor K, Weichenthal M, Walewski J, Fisher D, McNeeley M, Gru AA, Brown L, Palanca-Wessels MC, Lisano J, Onsum M, Bunn V, Little M, Trepicchio WL, Dummer R. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. Eur J Cancer. 2021 May;148:411-421. doi: 10.1016/j.ejca.2021.01.054. Epub 2021 Mar 29. PubMed 33794441 ↗
  • Valipour A, Jager M, Wu P, Schmitt J, Bunch C, Weberschock T. Interventions for mycosis fungoides. Cochrane Database Syst Rev. 2020 Jul 7;7(7):CD008946. doi: 10.1002/14651858.CD008946.pub3. PubMed 32632956 ↗
  • Dummer R, Prince HM, Whittaker S, Horwitz SM, Kim YH, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown L, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Huen A, Walewski J, Wang Y, Lisano J, Richhariya A, Feliciano J, Zhu Y, Bunn V, Little M, Zagadailov E, Dalal MR, Duvic M. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. Eur J Cancer. 2020 Jul;133:120-130. doi: 10.1016/j.ejca.2020.04.010. Epub 2020 Jun 2. PubMed 32502876 ↗
  • Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dreno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7. PubMed 28600132 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2012 to primary completion in May 2016, 47 months.

Results were first posted in Mar 2018, 1 year 9 months after primary completion. A results delay was requested in Feb 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2012
First posted
Apr 17, 2012
StartActual
Jun 11, 2012
Primary completionActual
May 31, 2016
CompletionActual
Jul 6, 2018
Results delay requested
Feb 2, 2017
Results first posted
Mar 16, 2018
Last update
Jan 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01578499
Collaborators
Seagen Inc.
Responsible party
Sponsor
First posted
Apr 17, 2012
Start date
Jun 11, 2012
Primary completion
May 31, 2016
Completion
Jul 6, 2018
Results posted
Mar 16, 2018
Last update
Jan 5, 2021

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brentuximab Vedotin

Start the discussion